Summary & Overview
HCPCS J9319: Romidepsin Injection, 0.1 mg
HCPCS Level II code J9319 denotes a lyophilized injectable formulation of romidepsin measured per 0.1 mg. Romidepsin is an antineoplastic agent used in oncology infusion settings; accurate coding of the drug unit is critical for claims processing, inventory management, and reimbursement for infusion services across payers. Nationally, precise HCPCS coding supports consistent billing for high-cost oncology therapies and informs utilization and cost oversight.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what this code represents clinically and operationally, the typical sites where the service is rendered, and the scope of payer coverage considered. The publication provides benchmark-oriented context on coding practice, highlights policy or coverage considerations that commonly affect injectable oncology agents, and outlines clinical context for infusion administration.
Where specific data elements were not provided in the input, the publication notes that those items are not available in the input. The piece is intended for a national audience of billing managers, oncology clinic administrators, and policy analysts seeking a concise reference on HCPCS Level II code J9319.
Billing Code Overview
HCPCS Level II code J9319 represents an injection formulation of romidepsin, lyophilized, dosed per 0.1 mg. The code describes the drug product and unit of measure for billing intravenous chemotherapy administration.
Service Type: Chemotherapy drug administration (injectable antineoplastic agent)
Typical Site of Service: Outpatient infusion center or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma receiving intravenous chemotherapy in an outpatient oncology infusion center. The medication J9319 represents romidepsin, lyophilized, supplied per 0.1 mg vial; dosing is weight- or body-surface-area–based and prepared by pharmacy staff under sterile technique in an oncology clinic or hospital outpatient infusion suite. The clinical workflow includes diagnosis and consent, baseline lab assessment (CBC, CMP, ECG), chemotherapy order verification by the oncologist, sterile compounding by pharmacy, administration by an infusion nurse via peripheral IV or central venous access, monitoring for infusion reactions and cardiac effects during and after infusion, and documentation of dose, lot number, and any wastage. Typical sites of service are hospital outpatient departments, freestanding oncology infusion centers, and physician office-based infusion suites. Common encounter details include premedication as ordered, administration over the recommended infusion time, and post-infusion observation for adverse events such as nausea, hematologic toxicity, or ECG changes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no specific modifier applies to the service |